mProX™ Human CDK4 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1069	Magic™ Human CDK4/CycD3 in Vitro Assay	Human		Kinase Assay
S01YF-1122-KX1070	Magic™ Human CDK4/CycD1 in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

CDK4

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

MCF7; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research; Pigmentation Research

Related Diseases

Melanoma, Cutaneous Malignant 3 and Hereditary Melanoma. Among its related pathways are Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects and Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6

Gene ID

1019

UniProt ID

P11802

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The human CDK4 gene encodes cyclin-dependent kinase 4, often referred to as cell division protein kinase 4. The cyclin-dependent kinase family includes CDK4. This gene codes for a protein that belongs to the Ser/Thr protein kinase family. The gene products of S. cerevisiae cdc28 and S. pombe cdc2 are quite similar to this protein. It is a catalytic subunit of the protein kinase complex and plays a crucial role in the G1 phase of the cell cycle. This kinase's activity is limited to the G1-S phase, which is governed by the CDK inhibitor p16INK4a and the regulatory subunits D-type cyclins. It has been demonstrated that this kinase is in charge of phosphorylating the retinoblastoma gene product (Rb). The customized CDK4 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Thomas

The mouse CDK4 cell line proved to be an invaluable tool in my experiments. Its excellent performance and reproducibility greatly contributed to the success of my research project. Jun 07 2023

chat Verified Customer

chat Paul

The CDK4 cell line I purchased was incredibly effective in my research. Aug 16 2022

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Generated CDK4/6 Inhibitor-Resistant Cell Lines Have Dramatically Increased CDK6 Protein Expression.

Together with a gradual decline in CDK1 expression, there was also a slight stepwise increase in cyclin E levels. All resistant cells retained RB phosphorylation at the CDK4/6 sites Ser807/Ser811, as well as at Thr356.

Ref: Cornell, Liam, et al. "MicroRNA-mediated suppression of the TGF-β pathway confers transmissible and reversible CDK4/6 inhibitor resistance." Cell reports 26.10 (2019): 2667-2680.

Pubmed: 30840889

DOI: 10.1016/j.celrep.2019.02.023

Research Highlights

D-type cyclins, along with cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), are the activating partners that connect the extracellular milieu to the central machinery of the cell cycle. In a number of cancer forms, constitutive activation of cyclin D-CDK4/6 is the primary cause of carcinogenesis.
Fassl, Anne, Yan Geng, and Piotr Sicinski. "CDK4 and CDK6 kinases: From basic science to cancer therapy." Science 375.6577 (2022): eabc1495.
Pubmed: 35025636 DOI: 10.1126/science.abc1495

These studies established the basic idea that CDK4/6 inhibitors could be useful in the treatment of cancer, especially when paired with the suppression of related mitogen-dependent signal transduction pathways.
Sherr, Charles J., David Beach, and Geoffrey I. Shapiro. "Targeting CDK4 and CDK6: from discovery to therapy." Cancer discovery 6.4 (2016): 353-367.
Pubmed: 26658964 DOI: 10.1158/2159-8290.CD-15-0894